Sol-Gel Technologies Reports Third Quarter 2018 Financial Results
November 13, 2018 16:05 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Technologies Announces Participation in Upcoming Investor Conference
November 05, 2018 16:05 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Technologies Announces an Additional Collaborative Agreement for a Generic Product Candidate with Perrigo
November 01, 2018 16:05 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III Epsolay® Program for the Treatment of Papulopustular Rosacea
September 25, 2018 16:05 ET
|
Sol-Gel Technologies Ltd.
Patient enrollment of the pivotal Phase III Epsolay clinical trials is on schedule Top-line results expected in 2019 NESS ZIONA, Israel, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies...
Sol-Gel Technologies Names Jonathan B. Siegel to the Board of Directors
September 13, 2018 16:05 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Technologies Provides Program Update for TWIN for the Treatment of Acne Vulgaris
September 04, 2018 16:05 ET
|
Sol-Gel Technologies Ltd.
Announces Positive End-of-Phase II Meeting with the FDA Receives Special Protocol Assessment (SPA) Agreement from FDA Company expects to commence the TWIN Phase III clinical trials in the fourth...
Sol-Gel Technologies Announces Collaborative Agreement for Generic Product with Perrigo
August 15, 2018 16:05 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Technologies Reports Second Quarter 2018 Financial Results
August 08, 2018 07:05 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Technologies Initiates Pivotal Phase III Clinical Program for Papulopustular Rosacea
June 18, 2018 16:33 ET
|
Sol-Gel Technologies Ltd.
First subject dosed in pivotal Phase III program evaluating Epsolay® in subjects with papulopustular rosacea Two Phase III trials expected to enroll a total of 700 subjects Top-line data expected...
Sol-Gel Technologies Announces Participation in Upcoming Investor Conferences
May 29, 2018 16:05 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, May 29, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ:SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and...